Abstract
Atherosclerosis, the primary cause of cardiovascular disease, is a complex and multifactorial pathology resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of the role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) damage may be directly involved in the development of multiple mechanisms of atherogenesis. Recent findings show that several heteroplasmic mutations of mtDNA are related to atherosclerosis, coronary heart disease and several atherosclerosis-related diseases such as arterial hypertension and diabetes mellitus. Therefore, heteroplasmic mtDNA mutations could represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies. This review is focused on the latest findings in the studies of mutations of mitochondrial genome, which are associated with atherosclerosis and atherosclerosis- related diseases.
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, coronary heart disease.
Current Pharmaceutical Design
Title:Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Volume: 21 Issue: 9
Author(s): Igor A. Sobenin, Andrey V. Zhelankin, Konstantin Y. Mitrofanov, Vasily V. Sinyov, Margarita A. Sazonova, Anton Y. Postnov and Alexander N. Orekhov
Affiliation:
Keywords: Atherosclerosis, atherogenesis, mitochondrial DNA, mutations, heteroplasmy, coronary heart disease.
Abstract: Atherosclerosis, the primary cause of cardiovascular disease, is a complex and multifactorial pathology resulted from the harmful interactions between genetic and environmental factors. There is a growing body of evidence in support of the role of mitochondrial factors in the pathogenesis of atherosclerosis. Impaired mitochondrial function and structural and qualitative changes in mitochondrial components such as mitochondrial DNA (mtDNA) damage may be directly involved in the development of multiple mechanisms of atherogenesis. Recent findings show that several heteroplasmic mutations of mtDNA are related to atherosclerosis, coronary heart disease and several atherosclerosis-related diseases such as arterial hypertension and diabetes mellitus. Therefore, heteroplasmic mtDNA mutations could represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies. This review is focused on the latest findings in the studies of mutations of mitochondrial genome, which are associated with atherosclerosis and atherosclerosis- related diseases.
Export Options
About this article
Cite this article as:
Sobenin A. Igor, Zhelankin V. Andrey, Mitrofanov Y. Konstantin, Sinyov V. Vasily, Sazonova A. Margarita, Postnov Y. Anton and Orekhov N. Alexander, Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013133000
DOI https://dx.doi.org/10.2174/1381612820666141013133000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets Recent Progress in Biological Activities of Indole and Indole Alkaloids
Mini-Reviews in Medicinal Chemistry Strategies to Reduce Oxidative Stress in Glaucoma Patients
Current Neuropharmacology Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Patent Selections:
Recent Patents on Cardiovascular Drug Discovery The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Obesity and Gestational Diabetes in Pregnant Care and Clinical Practice
Current Vascular Pharmacology Medial Vascular Calcification in Diabetes Mellitus and Chronic Kidney Disease: The Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Epicardial Adipose Tissue As New Cardio-Metabolic Risk Marker and Potential Therapeutic Target in the Metabolic Syndrome
Current Pharmaceutical Design Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Current Drug Therapy Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Coumarin and Derivates as Lipid Lowering Agents
Current Topics in Medicinal Chemistry Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters
Current Drug Metabolism Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Editorial: Can Statins Mitigate the Adverse Cardiovascular Effects of Smoking?
Current Vascular Pharmacology Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy